Ken Fisher Fisher Asset Management
Ken Fisher is the founder and executive chairman of Fisher Investments, a global money management firm overseeing billions of dollars in assets. He gained early recognition for pioneering the use of the price-to-sales ratio in stock analysis and wrote the long-running “Portfolio Strategy” column in Forbes. Over the years, Fisher has authored numerous books on investing and wealth management, many of which have become bestsellers.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$1.88B |
| 2 |
Pfizer
PFE
|
+$1.41B |
| 3 |
iShares 7-10 Year Treasury Bond ETF
IEF
|
+$1.17B |
| 4 |
Cisco
CSCO
|
+$1.1B |
| 5 |
Novartis
NVS
|
+$984M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abbott
ABT
|
+$1.21B |
| 2 |
Adobe
ADBE
|
+$1.06B |
| 3 |
Stryker
SYK
|
+$955M |
| 4 |
Boston Scientific
BSX
|
+$695M |
| 5 |
Banco Santander
SAN
|
+$684M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.16% |
| 2 | Financials | 17.3% |
| 3 | Industrials | 10.45% |
| 4 | Healthcare | 9.91% |
| 5 | Energy | 8.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
226
SLB Ltd
SLB
$72.6B
| $54.3M | 0.02% |
1,056,438
+11,420
| +1% | +$554K |
|
227
iShares MSCI United Kingdom ETF
EWU
$4.17B
| $54M | 0.02% |
1,185,082
+21,108
| +2% | +$973K |
|
228
Sally Beauty Holdings
SBH
$1.46B
| $53.4M | 0.02% |
3,852,679
-264,758
| -6% | -$4.04M |
|
229
Matador Resources
MTDR
$6B
| $52.5M | 0.02% |
830,292
+139,043
| +20% | +$6.96M |
|
230
Huntington Bancshares
HBAN
$34.5B
| $51.3M | 0.02% |
3,278,424
+78,335
| +2% | +$1.34M |
|
231
Macerich
MAC
$7.22B
| $51.2M | 0.02% |
2,706,935
-186,698
| -6% | -$3.54M |
|
232
Cytokinetics
CYTK
$10.9B
| $50.6M | 0.02% |
768,264
-54,621
| -7% | -$3.47M |
|
233
United Bankshares
UBSI
$6.62B
| $50.2M | 0.02% |
1,211,131
+28,190
| +2% | +$1.17M |
|
234
iShares Expanded Tech-Software Sector ETF
IGV
$12.5B
| $50.1M | 0.02% |
626,482
-59,518
| -9% | -$5.27M |
|
235
Fidelity Nasdaq Composite Index ETF
ONEQ
$10.2B
| $50M | 0.02% |
588,759
-8,747
| -1% | -$786K |
|
236
Century Aluminum
CENX
$4.44B
| $50M | 0.02% |
851,301
-15,643
| -2% | -$784K |
|
237
iShares 1-3 Year Treasury Bond ETF
SHY
$25.5B
| $49.9M | 0.02% |
604,783
+37,910
| +7% | +$3.14M |
|
238
Home BancShares
HOMB
$6.25B
| $48.9M | 0.02% |
1,815,609
-141,319
| -7% | -$3.98M |
|
239
Pricesmart
PSMT
$5.94B
| $48.2M | 0.02% |
320,481
+103,481
| +48% | +$15.1M |
|
240
United Rentals
URI
$66.5B
| $47.8M | 0.02% |
65,572
-1,162
| -2% | -$976K |
|
241
Otis Worldwide
OTIS
$27.3B
| $47.7M | 0.02% |
619,482
-4,521
| -0.7% | -$396K |
|
242
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
$21.9B
| $47.7M | 0.02% |
437,813
-21,489
| -5% | -$2.51M |
|
243
Artisan Partners
APAM
$2.82B
| $47.7M | 0.02% |
1,310,131
-130,349
| -9% | -$5.33M |
|
244
Arcus Biosciences
RCUS
$3.55B
| $47.3M | 0.02% |
2,190,404
+240,616
| +12% | +$5.2M |
|
245
Pegasystems
PEGA
$4.94B
| $47.2M | 0.02% |
1,108,232
-62,145
| -5% | -$2.89M |
|
246
ICICI Bank
IBN
$109B
| $46.8M | 0.02% |
1,806,628
+22,930
| +1% | +$672K |
|
247
Denali Therapeutics
DNLI
$3.86B
| $46.8M | 0.02% |
2,436,895
-152,508
| -6% | -$3.03M |
|
248
Belden
BDC
$4.56B
| $45.5M | 0.02% |
395,822
+26,046
| +7% | +$3.28M |
|
249
Post Holdings
POST
$4.21B
| $45.3M | 0.02% |
458,453
+216,352
| +89% | +$22M |
|
250
Xylem
XYL
$27.3B
| $45.2M | 0.02% |
378,385
-23,954
| -6% | -$3.14M |
|
Similar funds
Ken Fisher's Q1 2026 Portfolio in Review
As of Q1 2026, Ken Fisher held 1,133 positions worth $295B, up 0.65% from $293B the previous quarter. Its ten largest holdings account for 33% of the portfolio.
Ken Fisher's Q1 2026 filing shows 116 new, 416 increased, 461 reduced and 117 closed positions. Its largest new stake was Portfolio Building Block World Pharma and Biotech Index ETF: 28,040,859 shares worth $717M. The largest sale was Abbott, an estimated $1.21B.
By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 25% a quarter earlier, followed by Financials and Industrials.
- Ken Fisher's largest Q1 2026 buy was Portfolio Building Block World Pharma and Biotech Index ETF: 28,040,859 shares worth $717M.
- Ken Fisher added most to AbbVie in Q1 2026, an estimated $1.88B increase.
- Ken Fisher's biggest Q1 2026 reduction was Abbott, cutting an estimated $1.21B.
- Ken Fisher fully exited Trip.com Group in Q1 2026, selling an estimated $175M.
- Ken Fisher's ten largest holdings make up 33% of its $295B portfolio in Q1 2026.
- Ken Fisher opened 116 new positions and closed 117 in Q1 2026.
- Ken Fisher's portfolio value rose 0.65% quarter-over-quarter to $295B.
Based on Fisher Asset Management's 13F filing for Q1 2026, filed 5 May 2026.